NewLink Genetics Corporation
36
0
0
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
41.7%
15 terminated/withdrawn out of 36 trials
57.1%
-29.4% vs industry average
6%
2 trials in Phase 3/4
25%
5 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (36)
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Role: lead
Immunotherapy Study for Patients With Stage IV Melanoma
Role: lead
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
Role: lead
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Role: lead
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Role: lead
Immunotherapy Study for Metastatic Renal Cell Cancer
Role: lead
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
Role: lead
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Role: lead
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Role: lead
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Role: lead
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Role: lead
NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
Role: lead
A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
Role: lead
Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers
Role: lead
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Role: lead
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Role: lead
Vaccine Treatment for Hormone Refractory Prostate Cancer
Role: lead
Vaccine Treatment for Advanced Malignant Melanoma
Role: lead
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Role: lead
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Role: lead